このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Disc Medicine 過去の業績

過去基準チェック /06

Disc Medicineの収益は年平均-36.9%で減少しているが、Biotechs業界はgrowingで15.5%年平均の収益となった。

主要情報

-36.9%

収益成長率

37.7%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-23.8%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Jun 14

Disc Medicine: What's Behind The Huge Rally

Jan 31

収支内訳

Disc Medicine の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:IRON 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-81	25	73
31 Dec 23	-76	22	69
30 Sep 23	-64	20	57
30 Jun 23	-66	18	50
31 Mar 23	-60	17	46
31 Dec 22	-47	14	33
30 Sep 22	-44	11	29
30 Jun 22	-37	10	27
31 Mar 22	-37	7	26
31 Dec 21	-36	6	25

質の高い収益: IRONは現在利益が出ていません。

利益率の向上: IRONは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: IRONは利益が出ておらず、過去 5 年間で損失は年間36.9%の割合で増加しています。

成長の加速: IRONの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IRONは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: IRONは現在利益が出ていないため、自己資本利益率 ( -23.84% ) はマイナスです。

Disc Medicine 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Disc Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $177.984 million.

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria (EPP)

New major risk - Revenue and earnings growth

Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer

Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Key Executive notifies of intention to sell stock

Disc Medicine: What's Behind The Huge Rally

Key Executive notifies of intention to sell stock

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Disc Medicine, Inc Announces Retirement of Brian MacDonald as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Independent Director notifies of intention to sell stock

Disc Presents Initial Positive Data from Ongoing Phase 1B/2 Trial of Disc-0974 in Patients with Myelofibrosis (Mf) and Anemia At the 65Th American Society of Hematology (Ash) Annual Meeting

General Counsel notifies of intention to sell stock

General Counsel exercised options and sold US$176k worth of stock

General Counsel notifies of intention to sell stock

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine Announces Departure of Joanne Bryce as Chief Financial Officer

Disc Medicine, Inc. Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

Chief Financial Officer notifies of intention to sell stock

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Disc Medicine, Inc. Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria at European Hematology Association (EHA) 2023 Congress

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress

Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

No independent directors

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06